, Revue neurologique, vol.163, pp.637-645, 2007.
, Interferon beta-1b is effective in relapsingremitting multiple sclerosis. I. Clinical results of a multicenter, randomized, doubleblind, placebo-controlled trial, The IFNB Multiple Sclerosis Study Group, vol.43, pp.655-61, 1993.
,
Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis, Ann Neurol, vol.39, pp.285-94, 1996. ,
, PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis, Lancet, vol.352, pp.1498-504, 1998.
Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up, J Interferon Res, vol.13, issue.5, pp.333-373, 1993. ,
Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis, Neurology, vol.44, issue.3, pp.406-419, 1994. ,
Hanestad BRType I interferons and the quality of life of multiple sclerosis patients. Results from a clinical trial on interferon alfa-2a, Mult Scler, vol.5, issue.5, pp.317-339, 1999. ,
, The Once Weekly Interferon for MS Study Group. Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study, Neurology, vol.53, issue.4, pp.679-86, 1999.
,
, European Oral Interferon Beta-1a in Relapsing-Remitting MS Study GroupOral interferon beta-1a in relapsing-remitting multiple sclerosis: a double-blind randomized study, Mult Scler, vol.9, issue.4, pp.342-350, 2003.
A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis, N Engl J Med, vol.317, issue.7, pp.408-422, 1987. ,
A placebo-controlled, double-blind, randomized, twocenter, pilot trial of Cop 1 in chronic progressive multiple sclerosis, 1991. ,
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group, Neurology, vol.45, issue.7, pp.1268-76, 1995. ,
European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group, Annals of neurology, vol.49, issue.3, pp.290-297, 2001. ,
, European Study Group on interferon ?-1b in secondary progressive MS. Placebocontrolled multicenter randomized trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis, Lancet, vol.352, pp.1491-1498, 1998.
, The North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS. Results from a 3-year controlled study, Neurology, vol.63, pp.1788-95, 2004.
, Secondary progressive efficacy clinical trial of recombinant interferon beta 1-a in MS (Spectrims) study group. Randomized controlled trial of interferon beta 1a in secondary progressive MS. Clinical results, Neurology, vol.56, pp.1496-504, 2001.
Benefit of interferon beta-1a on MSFC progression in secondary progressive MS, Neurology, vol.59, pp.679-87, 2002. ,
Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis, J Neurol Neurosurg Psychiatry, vol.75, pp.706-716, 2004. ,
Final analysis of the European multicenter trial on INF-1b in secondary progressive MS, Neurology, vol.57, pp.1969-75, 2001. ,
Interferon beta-1b in secondary progressive MS. A combined analysis of the two trials, Neurology, vol.63, pp.1779-87, 2004. ,
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes, Neurology, vol.67, pp.1-8, 2006. ,
Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis, N Engl J Med, vol.343, pp.898-904, 2000. ,
Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised sudy, Lancet, vol.357, issue.9268, pp.1576-82, 2001. ,
Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomized, double-blind, placebo-controlled trial, Lancet, vol.374, issue.9700, pp.1503-1514, 2009. ,
Diagnostic Criteria for multiple Sclerosis: 2005 Revisions to the "McDonald Criteria, Ann Neurol, vol.58, pp.840-846, 2005. ,
, The PRISMS Study group & the University of British Columbia MS/MRI analysis group. PRISMS-4: Long term efficacy of interferon beta-1a in relapsing MS, Neurology, vol.56, pp.1628-1664, 2001.
Prospective assessment of changing from placebo to IFN beta-1a in relapsing MS : The PRISMS study, J Neurol Sci, vol.237, pp.45-52, 2005. ,
Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients, Multiple Sclerosis, vol.11, pp.626-660, 2005. ,
Long term follow-Up of the Original Interferon-?1b Trial in Multiple Sclerosis: Design and Lessons From a 16-Year Observational Study, Clinical Therapeutics, vol.31, issue.8, pp.1724-1760, 2009. ,
Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years, Multiple sclerosis, vol.6, issue.4, pp.255-66, 2000. ,
Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial, Multiple sclerosis, vol.9, issue.6, pp.585-91, 2003. ,
Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data, Acta neurologica Scandinavica, vol.111, issue.1, pp.42-49, 2005. ,
A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients, Multiple sclerosis, vol.12, issue.3, pp.309-329, 2006. ,
Long-term followup of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial, Multiple sclerosis, vol.13, issue.4, pp.502-510, 2007. ,
Interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event, Neurology, vol.66, issue.5, pp.678-84, 2006. ,
Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis : a 3-year follow-up analysis of the BENEFIT study, Lancet, vol.370, pp.389-97, 2007. ,
Long-term of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis : 5-year active treatment extension of the phase 3 BENEFIT trial, Lancet Neurology, vol.8, issue.11, pp.987-97, 2009. ,
Interferon b in relapsing-remitting multiple sclerosis. An eight year experience in a specialist multiple sclerosis center, J Neurol, vol.252, pp.795-800, 2005. ,
Long term clinical experience with weekly interferon beta-1a in relapsing multiple sclerosis, Europ J of Neurol, vol.13, pp.1014-1035, 2006. ,
How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?, Neurology, vol.69, pp.1498-507, 2007. ,
New Natural History of interferon b Treated Relapsing Multiple Sclerosis, Ann Neurol, vol.61, pp.300-306, 2007. ,
Disease progression among multiple sclerosis patients before and during a diseasemodifying drug program: a longitudinal population-based evaluation, Multiple Sclerosis, vol.15, issue.11, pp.1286-94, 2009. ,
Longterm follow up of glatiramer acetate compassionate use in Belgium, Acta neurologica Belgica, vol.105, issue.2, pp.81-86, 2005. ,
A longitudinal observational study of cohort of patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate, Eur J Neurol, vol.14, issue.11, pp.1266-74, 2007. ,
for the Italian Multiple Sclerosis Database Network (MSDN) Group. Real-Life Impact of Early Interferon Therapy in Relapsing Multiple Sclerosis, Ann Neurol, vol.66, pp.513-520, 2009. ,
Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS, Neurology, vol.67, pp.944-953, 2006. ,
Hohlfeld R and The European IFNb-1a DoseComparison Study Investigators. Interferon b-1a in relapsing multiple sclerosis: fouryear extension of the European IFNb-1a Dose-Comparison Study, Multiple Sclerosis, vol.10, pp.139-144, 2004. ,
Results of an ongoing, open-label, safety extension study of interferon beta-1a (Avonex) treatment in multiple sclerosis, Int J MS Care, vol.1, pp.1-6, 1999. ,
Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis, Eur J Neurol, vol.13, issue.5, pp.471-475, 2006. ,
Therapeutic outcome 3 years after switching og immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina, Eur J Neurol, vol.15, pp.386-93, 2008. ,
Glatiramer acetate in treatment-naive and prior interferon-beta-1btreated multiple sclerosis patients, Acta Neurologica Scandinavica, vol.113, issue.6, pp.378-86, 2006. ,
DOI : 10.1111/j.1600-0404.2006.00627.x
Effects of interferon beta-1a and-1b over time: 6-year results of an observational head-to-head study, Acta Neurol Scand, vol.113, pp.241-248, 2006. ,
Outcome of beta-interferon treatment in relapsing-remitting multiple sclerosis: a Bayesian analysis, J Neurol, vol.254, pp.1547-54, 2007. ,
Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study, Stat Med, vol.23, pp.2937-2960, 2004. ,
Propensity score methods for bias reduction in the comparison of treatment to a non-randomized control group, Stat Med, vol.17, pp.2265-2281, 1998. ,
EDMUS, a European database for multiple sclerosis, J Neurol Neurosurg Psychatry, vol.55, pp.671-676, 1992. ,
DOI : 10.1136/jnnp.55.8.671
URL : https://jnnp.bmj.com/content/55/8/671.full.pdf
New diagnostic criteria for multiple sclerosis : guidelines for research protocols, Ann Neurol, vol.13, pp.227-231, 1983. ,
DOI : 10.1002/ana.410130302
Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis, Ann Neurol, vol.50, pp.121-127, 2001. ,
Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria, Ann Neurol, vol.59, issue.4, pp.727-728, 2006. ,
DOI : 10.1002/ana.22366
URL : http://europepmc.org/articles/pmc3084507?pdf=render
Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS), Neurology, vol.33, pp.1444-52, 1983. ,
DOI : 10.1212/wnl.33.11.1444
URL : http://n.neurology.org/content/33/11/1444.full.pdf
Evidence for a two-stage disability progression in multiple sclerosis, Brain, vol.133, pp.1900-1913, 2010. ,
DOI : 10.1093/brain/awq076
URL : https://academic.oup.com/brain/article-pdf/133/7/1900/927470/awq076.pdf
Highdimensional propensity score adjustment in studies of treatment effects using health care claims data, Epidemiology, vol.20, issue.4, pp.523-527, 2009. ,
The natural history of multiple sclerosis: a geographically based study. 2. Predictive values of the early clinical course, Brain, vol.6, pp.1419-1447, 1989. ,
Relapses and progression of disability in multiple sclerosis, New England Journal of Medicine, vol.343, pp.1430-1438, 2000. ,
Adeleine P. early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process, Brain, vol.126, pp.770-82, 2003. ,
Disability profile of MS did not change over 10 years in a population-based prevalence cohort, Neurology, vol.62, pp.601-607, 2004. ,
Disability progression in multiple sclerosis is slower than previously reported, Neurology, vol.66, pp.172-179, 2006. ,
DOI : 10.1212/01.wnl.0000194259.90286.fe
EDSS natural history atlas: MS disability progression in Nova Scotia, ECTRIMS conference, vol.14, issue.1, p.540, 1979. ,
Natural history of multiple sclerosis in a population-based cohort, Eur J Neurol, vol.15, pp.916-937, 2008. ,
and the National Multiple Sclerosis Society (USA) Task Force on Placebo-Controlled Clinical Trials in MS. Placebo-controlled clinical trials in multiple sclerosis: ethical considerations, Ann Neurol, vol.49, pp.677-81, 2001. ,
The cost of delaying treatment in multiple sclerosis: what is lost is not regained, Neurology, vol.56, p.1620, 2001. ,
Observational studies of treatment effectiveness: some cautions, Ann Intern Med, vol.140, pp.923-927, 2004. ,
Estimating causal effects of public health education campaigns using propensity score methodology, Eval Program Plann, vol.28, pp.209-229, 2005. ,
Assessing the sensitivity of regression results to unmeasured confounders n observational studies, Biometrics, vol.54, pp.948-63, 1998. ,
Rare outcomes, common treatments: analytic strategies using propensity scores, Ann Intern Med, vol.137, pp.693-698, 2002. ,
New perspectives in the natural history of multiple sclerosis, Neurology, vol.74, pp.2004-2019, 2010. ,
Age at disability milestones in multiple sclerosis, Brain, vol.129, pp.595-605, 2006. ,
, , vol.21, 2011.
, , p.3581
,
,